lazur
3 weeks ago
I don't see any movement on MJ at the fed level until at least a month or two after inauguration. The question will be, would passage (safe banking, rescheduling) be one of those "In the first 100 days" items for either president/king/queen that gets elected for the next four years. It could be an easy win to chalk up and prove some competency, progress, action in either administration. But perhaps sniping will rule the day next year rather than doing anything meaningful in congress. I see another impeachment attempt of Biden is afoot for when congress comes back from summer recess - more time and dollars well spent by congress rather than doing their job.
If SHWZ can consistently show net profits between now and then, yes, a bump is possible. And with the stock in the gutter, getting back to sixty cents would be a big percentage bump for traders.
Drugdoctor
3 weeks ago
Of course the politicians won't do a thing this year, as nothing will happen with weed before the November elections now. But just maybe.... next year as either party at least passes safe banking, and the company implements cost cutting measures, the markets in Colorado and New Mexico at least stabilize, and the company reports NET PROFITS for at least a few quarters. If that happens and they regain OTCQX trading status, I can see the Marijuana funds scrambling to add these cheap shares, and we have already seen how just their buying can move this stock. Ok... it's a waiting game now.
lazur
3 weeks ago
Right Doc, languishes probably through the end of the year, easily. They best hope they don't find any irregularities missed prior as well. But even if it all gets resolved next year, no surprises, and SHWZ says, "Hey everybody, we're back!" they may be saying that to an even emptier room than the one they are in now. They couldn't get people to care about the stock before, now, that's a steep hill they will need to climb to even get penny traders to take interest again. Beyond someone buying them for peanuts, I don't see a compelling upside for quite some time.
Drugdoctor
3 weeks ago
No it's not, lol. It was anticipated and expected. I posted that it might happen, months ago.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174735518
The filing rules require that, like stepping stones over a flowing river, that the financials have to be audited and accepted, to be used for subsequent filings starting points. So if the 2023 filings are not re-completed then they can't be used as a basis for inclusion as a starting point for 2024 filings, even though they have the numbers for the quarter. But once the old filings are resubmitted, then we will likely see a fast process for the 2024 filings to be filed. It's a tedious process, but obviously one they are working very diligently upon, and will get completed, hopefully by the end of this year.
Drugdoctor
3 weeks ago
OMG - NT10Q filed State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.
Medicine Man Technologies, Inc. (the “Company”) is unable to file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 (the “Quarterly Report on Form 10-Q”) on or prior to August 14, 2024, without unreasonable effort and expense for the reasons stated below.
The ongoing impact of the May 3, 2024, U.S. Securities Exchange Commission (“SEC”) order (the “SEC Order”) against B.F. Borgers CPA PC and Benjamin F. Borgers (individually and together, “Borgers”), pursuant to which the SEC suspended Borgers from appearing or practicing before the SEC as an accountant has been significantly challenging for the Company. Borgers was the Company’s independent auditor for the fiscal year ending December 31, 2023, during which time Borgers reviewed Company financial statements and performed reviews of interim financial statements.
In April, the Company engaged Baker Tilly to provide a re-audit of the Company’s year-end December 31, 2023 financial statements as filed on the Annual Report on Form 10-K and the interim quarterly statement for the three-months ending March 31, 2023, as filed in the Quarterly Report on Form 10-Q and the interim quarterly statement for the six-months ending June 30, 2023. The extent of the SEC Order’s impact has been significant on the Company’s financial statements as of and for the fiscal quarters ending March 31, 2024 and June 30, 2024, to be included in the Quarterly Report filed on Form 10-Q, and its financial statements as of and for the year ended December 31, 2023 included in its Annual Report on Form 10-K.
The impact of the SEC Order has required the Company to undergo a re-audit of the Company’s; (i) year-end December 31, 2023, financial statements as filed on the Annual Report on Form 10-K; (ii) the interim quarterly statement for the three-months ending March 31, 2023, as filed in the Quarterly Report on Form 10-Q, in order to file our Quarterly Report on Form 10-Q for the three-months ending March 31, 2024; and (iii) the interim quarterly statement for the six-months ending June 30, 2023, as filed in the Quarterly Report on Form 10-Q, in order to file our Quarterly Report on Form 10-Q for the six-months ended June 30, 2024. As stated in the SEC Order, Form 10-Q filings on or after the date of the SEC Order may not present financial information that has been reviewed by Borgers. Each quarterly period presented in Form 10-Q filings on or after the date of the SEC Order must be reviewed by a qualified, independent, PCAOB-registered public accountant that is permitted to appear or practice before the Commission.
Based on the scope of the re-audit of the Company’s financials noted above, Baker Tilly has had insufficient time to re-audit the Company’s financials by the required filing date of the Quarterly Report on Form 10-Q for the quarter ended June 30, 2024. The Company will use its best efforts to file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 within the extension period provided under rule 12b-25, however there can be no assurances as the timing of the filing is contingent on Baker Tilly’s re-audit of the Company’s financials noted above.
Drugdoctor
4 weeks ago
Obviously, the cost of the overhead of the distribution center was not enough to pay for itself in cost savings, and became a drain on earnings. I predicted that they would start closing weaker locations, months ago. And that is a good thing, as you can't continue to support and try to turn around locations that just aren't performing. My biggest concern is why they allowed themselves to get into the situation in the first place. Why did they take their finger off the pulse.
All those analysis and projections they were making, but they missed their targets?
I think Justin was hoping he could back away and let Nirup and the people that were running the company last year, continue to build the company, but they obviously were not capable of keeping up with the trends and were spending cash like it would never end.
Now Justin seems to be back in charge, as Dye Capital is hurting badly with the stock debacle, and I believe they will get it fixed by the end of 2024. I also believe he sees the need to report POSITIVE EARNINGS to support the stock, thus the closing of the cash bleeding distribution center. We as investors seem to have forgotten how we thought management was the greatest team in Cannabis, and they could do no wrong for years.
Some of us saw the debts spiraling out of control and the interest payments on the loans and PREFERRED STOCKS eating up all the profits. I don't think there will be anything that Dye can do about the debts coming due in 2025 except try to continue to pay interest on them, but he could SUSPEND THE PREFERRED DIVIDENDS for awhile and that would allow the company to become instantly profitable and likely would raise the stock price back into DOLLARLAND.
With the share price higher again, then he could use stock again to acquire more dispensaries and continue to build the store count as will be necessary to continue as a growing company. He knows he and his team fumbled, but it does appear he now has his finger on the pulse again, and hopefully we will see a much better outcome in 2025.
Drugdoctor
1 month ago
It totally depends on the state of the company as they get reinstated. If they were extremely profitable, (unlikely) and announced that NEWS while trading was on th e expert market, likely there would be a huge rally. Regardless, the share price would likely be back over .75, imo, just because they came back...
lazur
2 months ago
They've done such a great job of alienating investors, even a good ER will struggle to overcome that. There are other stocks, better managed companies, who didn't step in it and get moved to the Expert Market. So I would not expect anyone rushing back into this when it resumes trading, except flippers betting on a potential move when trading resumes and cashing out as soon as it does. IMHO, this rises only when someone makes an offer to buy it above where it's trading price. It's now a stock waiting on a hero, they've ruined any and all good will with investors.
Drugdoctor
2 months ago
Just kicking the can down the road!. It's a positive in the fact that they know damn well, the stock may not even be trading in February 2025, and they could then have to file bankruptcy because of over 30 million dollars in called loans for cash they don't have. So they have delayed this terrible scenario for at least 9 months. But, if the debtholder really wanted to help $SHWZ, they could have lowered the 15% interest rate down to at least 10%, And, of course, all of Dye's PREFERRED SHARES are still collecting those huge dividends which are eating up the profits of the company which could be used to pay down some of the debts. Dye could suspend the dividend payments until the company digs its way out of this debt hole if he wanted to, but NOOOOOOOOOOO. So anyone who invests in a company that now will have trading in its shares suspended for an indefinite period in the next day or two, based on this PR, will sadly see their cash become DEAD MONEY. Now, your thoughts?
Drugdoctor
2 months ago
DENVER, Colo., July 11, 2024 (GLOBE NEWSWIRE) -- Medicine Man Technologies, Inc., operating as Schwazze, (OTCPK: SHWZ) (Cboe CA: SHWZ) ("Schwazze" or the "Company"), today announced that it has finalized an agreement with two of its lenders to restructure its $15.0 million Altmore, LLC (“Altmore”) Loan Agreement and its $17.0 million Reynold Greenleaf & Associates LLC (“R. Greenleaf”) Promissory Note, both previously due in February 2025. This improves the Company's financial position by extending the maturities of both debt instruments to the end of 2025 and materially reducing amortization payments for the Altmore Loan Agreement.
Level up your trading with our powerful tools and real-time insights all in one place.
Hot Features
Premium
